Diabetes and Myelodysplasia: Understanding the Connection

Diabetes mellitus (DM) and myelodysplastic syndromes (MDS) share epidemiological associations and potential pathophysiological links, though causality is not fully established.

Epidemiological Associations

• Increased MDS Risk in DM: Meta-analyses show ~1.5–2x higher MDS incidence in diabetics (especially Type 2).
• Shared Risk Factors: Age (both increase with age), obesity, chronic inflammation, oxidative stress, environmental toxins (benzene, radiation).
• Genetic Overlap: Mutations in TET2, DNMT3A, ASXL1 (CHIP – clonal hematopoiesis of indeterminate potential) are age-related and associated with both DM and MDS/AML.

Pathophysiological Hypotheses

• Bone Marrow Microenvironment: Hyperglycemia → advanced glycation end-products (AGEs), ROS, pro-inflammatory cytokines → stromal damage, impaired hematopoiesis.
• Insulin/IGF-1 Signaling: Altered signaling may affect HSC proliferation/differentiation.
• Treatment Effects: Not standard DM meds. Rather, prior chemotherapy/radiation for other cancers (which may have included diabetic patients) causes therapy-related MDS. Some studies suggest metformin may be protective (AMPK activation), others show no effect or potential risk—data conflicting.

Clinical Implications

• Monitoring: Diabetics with unexplained cytopenias (anemia, thrombocytopenia, neutropenia) → CBC with differential, peripheral smear, consider bone marrow biopsy.
• Medication Review: Avoid unnecessary myelosuppressive drugs.
• Glycemic Control: Optimize to reduce microenvironment stress (theoretical benefit).
• CHIP Screening: Emerging; not routine.

Key Distinction

Diabetes does not "cause" MDS directly. The association likely reflects shared aging biology, inflammation, and clonal hematopoiesis dynamics.